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Abstract
Adenoid cystic carcinoma (ACC) is the second most common malignant neoplasm of the salivary glands. Most patients
survive more than 5 years after surgery and postoperative radiation therapy. The 10 year survival rate, however, drops to
40%, due to locoregional recurrences and distant metastases. Improving long-term survival in ACC requires the
development of more effective systemic therapies based on a better understanding of the biologic behavior of ACC. Much
preclinical research in this field involves the use of cultured cells and, to date, several ACC cell lines have been established.
Authentication of these cell lines, however, has not been reported. We performed DNA fingerprint analysis on six ACC cell
lines using short tandem repeat (STR) examinations and found that all six cell lines had been contaminated with other cells.
ACC2, ACC3, and ACCM were determined to be cervical cancer cells (HeLa cells), whereas the ACCS cell line was composed
of T24 urinary bladder cancer cells. ACCNS and CAC2 cells were contaminated with cells derived from non-human
mammalian species: the cells labeled ACCNS were mouse cells and the CAC2 cells were rat cells. These observations suggest
that future studies using ACC cell lines should include cell line authentication to avoid the use of contaminated or non-
human cells.
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Introduction
Adenoid cystic carcinoma (ACC) is the second most common
malignant neoplasm of the salivary glands [1–8]. It is composed of
duct-type epithelial cells and myoepithelial cells and shows
variable pathological patterns. ACC occurs most frequently in
men and women in their fifties. This malignancy arises in the
major and the minor salivary glands but is more common in the
minor salivary glands. As the tumor grows, it has a tendency to
invade nerves, resulting in pain, numbness, and/or paralysis. ACC
grows slowly and regional lymph node metastases are uncommon.
Most patients with ACC survive more than 5 years after surgery
and postoperative radiation therapy. Nevertheless, the survival
rate at 10 years drops to 40% due to locoregional recurrences and
distant metastases. Metastasis occurs most commonly in the lungs
and less commonly in the liver, brain and bone [3,4,8]. Distant
metastases can develop despite locoregional tumor control and can
occur more than ten years after initial therapy. Due to this
behavior, ACC is considered by some to be a systemic disease with
an unpredictable clinical course [7,8].
The best survival rates for ACC are gained by using a
combination therapy involving surgery and postoperative radia-
tion therapy [8]. Conventional chemotherapy has a poorly defined
role in the treatment of ACC. Improved systemic therapies are
clearly needed for ACC, and one important way to gain insight is
to better understand the biological behavior of ACC cells.
Cell lines are frequently used to identify diagnostic biomarkers
and for early studies of therapeutic development. To date,
approximately ten ACC cell lines including ACC2, ACC3, ACCM,
ACCS, ACCNS, and CAC2 have been established [9–16]. The
ACC cell lines are not housed in Biological Resources Centers
(BRCs). Rather, they have been exchanged between laboratories.
Despite their wide use in academic research, authentication of
the established ACC cell lines has not been performed. Very
recently, Choi et al reported that the ACC2, ACC3 and ACCM
had identical genotypes. On comparison to the genotypes of the
ATCC (American Type Culture Collection) cancer cell line
collection, they found that the genotype of the cells they tested was
identical to that of HeLa cells [17].
It is not yet clear whether alternative authenticated genuine ACC
cell lines are available among the rest of the ACC cell lines. We used
DNA fingerprint analysis short tandem repeat (STR) profiling to
authenticate the six ACC cell lines cited above, which include ACC2,
ACC3 and ACCM. STR profiling is currently accepted as an
international reference standard for human cell line authentication
[18]. Approximately 700 out of 1700 tumor cell lines at ATCC
are STR profiled (http://www.atcc.org/CulturesandProducts/
CellBiology/STRProfileDatabase/tabid/174/Default.aspx).
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6040STR profiling techniques were originally developed for forensic
applications [18]. The technology allows easy determination of a
cell line’s authenticity at minimal cost. We used the same system
that the ATCC and JCRB (Japanese Collection of Research
Bioresources) use for creating their databases (Promega’s Power-
Plex 1.2 system). This system covers eight STR loci. Each locus
consists of short repetitive sequence elements 4 to 5 base pairs in
length. These repeats are well-distributed throughout the human
genome and are a rich source of highly polymorphic markers,
which can be detected using the polymerase chain reaction (PCR).
Alleles of STR loci are differentiated by the number of copies of
the repeat sequence and are distinguished from one another using
fluorescence detection following electrophoretic separation. The
result is as a simple numerical code corresponding to the length of
the PCR products amplified at each locus. This code enables
identification of individuals with unprecedented accuracy. In
combination with the amelogenin (AMEL) sex-typing gene,
complete matching probabilities of nine STR loci are less than
one in ten billion.
Results
Genetic profiling reveals that ACC2, ACC3 and ACCM
were contaminated with HeLa cells
We performed DNA fingerprint analysis of ACC2, ACC3, and
ACCM through STR examinations. We tested two different
batches of ACC2 from two unrelated laboratories (ACC2/Sa and
ACC2/Zh). Table 1 shows STR profiling for ACC2/Sa, ACC2/
Zh, ACC3, and ACCM cells. We also tested 12 human cell lines at
our institution, including HeLa cervical carcinoma cells. The
repeat numbers for the HeLa (Table 1) and other 11 cells (data not
shown) were perfectly or almost perfectly matched to their
numbers in the ATCC database. This result also confirmed that
contamination did not occur when we used these cells in our
laboratory during the last twelve years.
The ACC2 cell line was derived from a 28-year-old female
patient and ACC3 came from a 49-year-old male [9]. ACCM was
established from ACC2 as a highly metastatic subclone [10]. Our
STR analysis demonstrated that our ACC2, ACC3, and ACCM
cells had nearly identical electrophoretic profiles (Table 1, and
Figures 1 and S1, S2, S3, S4, S5, S6, S7, S8, S9, S10). A very
similar observation was reported from another laboratory [17].
Amelogenin (AMEL) gender-typing showed that all three cell lines
lacked a Y chromosome. This observation suggested that all three
cell lines were derived from a female patient. It is, however,
important to note that the Y chromosome is often lost in cultured
cells. Therefore it use as a gender discrimination tool is not always
accurate in cultured cells [19,20]. We found a small variation in
the von Willebrand factor gene (vWA) that even occurred between
the two ACC2 lines (Figure 1). This finding was confirmed by a
different set of STR analyses (Figure S1).
Surprisingly, the STR profiles of these three cell lines were almost
identical to that of HeLa cells, except for vWA in ACC2/Sa, ACC3
and ACCM (Table 1, and Figures 1 and S1). We purchased HeLa
cells from the ATCC and found that our HeLa cells had the same
STR profile as the ATCC HeLa cells. HeLa are used extensively
around the world, and are known as aggressive contaminators of
other cells [21]. There is no common stock of HeLa cells, and each
batch from each source is slightly different [21]. Studies have
demonstrated that HeLa cells, their subline HeLaS3, and their
cross-contaminants (Hep2, Intestine 407, KB, and Chang Liver) are
closely related by STR profiling, but are not necessarily identical. In
fact, there is even a slight discrepancy between three HeLaS3
subclones (CCL2.2, IFO50011 and JCRB9010) in the JCRB
database in D13S317, D5S818 and vWA STR profiling (Table S1).
We found that our ACC cells had a small variation in the vWA
locus: (16, 18), (17, 18), and (16, 17, 18). An identical vWA profiling
change was found in the HeLaS3 subclones (Table S1). Thus, we
attributed differences between them to genetic instability and
variations in cultivating conditions [21,22].
Various studies have determined that cross-contaminated cells
are defined as those that match at 80% or more of alleles in STR
analysis [22,23]. The percent matches of our three ACC cell lines to
HeLa cells were 100%, 97% or 94% (Table 1). These observations
suggest that the original ACC2, ACC3, and ACCM cells had been
replaced with HeLa cells. ACC2, ACC3 and ACCM were first
reported in 1986 and 1997, many years after the establishment of
HeLa cells in 1951 [21,23]. Therefore, it is possible that ACC2,
ACC3 and ACCM may have acquired the genetic changes
particularly in vWA due to passaging effects in HeLa cells [24].
Taken together, this data suggests that ACC2, ACC3, and
ACCM were actually HeLa cells.
ACCS was genetically identical to T24 urinary bladder
cancer cells
We also performed STR analysis on ACCS, another ACC cell
line (Table 2, and Figures S11 and S12). Because the ACCS line’s
genetic profile did not resemble those of other cell lines we tested
in this study (Table 1 and data not shown), we compared our
results with information in the ATCC and JCRB databases
(Table 2, http://cellbank.nibio.go.jp/str2/str006.html).
To our surprise, its profile was nearly identical to that of T24
urinary bladder cancer cells and their contaminants, EJ-1 and
ECV304 cells (Table 2). The percent matches of the STR profiles
of these cells to ACCS were 95% and 87%, suggesting that there
Table 1. STR DNA fingerprint analysis of HeLa, ACC2, ACC3, and ACCM cells.
STR Locus
Cell line AMEL CSF1PO D13S317 D16S539 D5S818 D7S820 TH01 TPOX vWA Percent match to HeLa
HeLa X 9, 10 12, 13.3 9, 10 11, 12 8, 12 7 8, 12 16, 18 100
ACC2/Sa X 9, 10 12, 13.3 9, 10 11, 12 8, 12 7 8, 12 16,17, 18 97
ACC2/Zh X 9, 10 12, 13.3 9, 10 11, 12 8, 12 7 8, 12 16, 18 100
ACC3 X 9, 10 12, 13.3 9, 10 11, 12 8, 12 7 8, 12 17, 18 94
ACCM X 9, 10 12, 13.3 9, 10 11, 12 8, 12 7 8, 12 17, 18 94
The table shows repeat numbers of allelic ladder components of eight STR loci and AMEL. Electrophoretic profiles of vWA and other markers for these cells are shown in
Figures 1 and S2, S3, S4, S5, S6, S7, S8, S9, S10.
doi:10.1371/journal.pone.0006040.t001
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common cross-contaminating cell line [22,26]. The expression of
HLA antigen on the cell surface revealed that EJ-1 cells share the
same genetic profile with the original T24 bladder cancer cells
[26]. ECV304 was initially reported as an endothelial cell line
derived from spontaneously transformed umbilical vein [27].
However, it was subsequently determined to be a contaminant of
T24 [22,25,28–30]. T24 is a chromosomally unstable cell line and
acquires secondary genetic changes [22,31]. This fact explains why
the STR result for ECV304 was not identical to that of T24
(Table 2). ECV304 lost one allele of D5S818 (5p21–q31) and
another allele of CSF1PO (5q33.3–q34) from the original T24
cells [25]. Interestingly, these deletions were also found in the
ACCS cells, suggesting that D5S818 and CSF1PO are deletion-
prone loci in T24 cells. In addition, the ACCS cells had a further
allelic deletion in TPOX (2p23-2pter). ACCS and ECV304 were
first reported in 1990, many years after T24 cells were established
in 1970 [27,32]. Therefore, it is possible that ACCS and ECV304
may have acquired their genetic changes due to passaging effects
in T24 cells [24].
Overall, we concluded that the ACCS cells were genetically
identical to T24 urinary bladder transitional cell carcinoma cells.
Figure 1. HeLa contaiminated-ACC2, ACC3, and ACCM demonstrate a variation in the von Willebrand factor gene (vWA).
Electrophoretic profiles of the vWA marker for HeLa, ACC2/Sa, ACC2/Zh, ACC3, and ACCM are shown. Complete STR profiling is shown in Table 1 and
Figures S2, S3, S4, S5, S6, S7, S8, S9, S10. A multiplex PCR reaction was performed using two-color detection fluorescent dye-linked primers. One ng of
each genomic DNA was independently amplified in a 25 ml reaction volume. The amplified PCR products were separated by capillary electrophoresis
on a 3730xI DNA Analyzer (Applied Biosystems) and analyzed using GeneMapper v4.0 software (Applied Biosystems). Cell lines for the study were
generously provided by Drs. Takashi Saku (ACC2/Sa and ACC3), Naishuo Zhu (ACC2/Zh), Kanemitsu Shirasuna (ACCS), Noriaki Tanaka (ACCM and
ACCNS), and Ruy Jaeger (CAC2). HeLa cells were purchased from the ATCC.
doi:10.1371/journal.pone.0006040.g001
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cells were from a rat cell line
We were unable to amplify any human polymorphic STR
markers in our ACCNS and CAC2 cells (data not shown). This
result suggested that these cells were not human cells. Cross-
contamination among cell lines is not limited to intraspecies
contamination, and interspecies contamination can occur. To test
if ACCNS and CAC2 cells were non-human, we performed a
cytochrome C oxidase subunit I (COI) DNA barcoding assay for
species identification [33]. This is a multiplex PCR-base assay to
detect cross-contaminations among the most common culture
species. The assay uses COI, a conserved mitochondrial gene,
whose use is a global standard for species identification [34]. The
59 end of the COI region, which is 648 nucleotide base pairs long
in most groups of higher animals, contains substantial interspecies
variation— yet intraspecies variation remains relatively low in
nearly all animals [34]. This approach enables the identification of
a wide array of animals with high confidence. This technique is
currently applied to species identification in cell cultures [33,35].
We isolated genomic DNA from ACCNS and CAC2 cells and
amplified it by PCR using multiplex 12 species-specific primer sets
designed to amplify a specifically sized product only in the
presence of target species [33]. We next separated the PCR
products in a 2% agarose gel and visualized them with ethidium
bromide (Figure 2). We used two sets of PCR primers. Lanes 3 and
5 included all 12 species-specific PCR primer sets, whereas we
eliminated mouse primer pairs in lanes 2 and 4. We used the
mouse-free PCR primer sets because they would not compete with
the human primer pair if the human genes were present in very
low copy levels. Lanes 2 and 3 show results from ACCNS cells and
lanes 4 and 5 show results for CAC2 cells. Lane 6 is a positive
control and lane 7 is a negative control. We found a 150 bp PCR
product in lane 3. This PCR product did not appear when the
mouse primer pairs were absent (lane 2). These observations
suggested that ACCNS cells were a mouse cell line. On the other
hand, lanes 4 and 5 showed 196 bp PCR products, indicating that
CAC2 cells were derived from rats. The PCR products were
further analyzed by sequencing, and we confirmed that ACCNS
cells were mouse cells and that CAC2 cells were rat cells (data not
shown).
Discussion
We investigated six established and widely-used ACC cell lines
and found that all six had been replaced with other cells (Table 3).
The cells labeled ACC2, ACC3, and ACCM were HeLa cells,
while the ACCS cells were human bladder cancer cells T24
(intraspecies cross-contamination). The putative ACCNS and
CAC2 cells were actually derived from mice (ACCNS) or rats
(CAC2; interspecies cross-contamination). Our ACC cells were
never cultured simultaneously with HeLa cells, and no T24, rat or
mouse cells were cultured in our incubators. Thus, we did not
cause the contamination. None of these cells were derived from
ACC patients. These results unfortunately call into question the
validity of results from prior studies using these cell lines.
Cell lines established from human tissues are extensively used to
study human diseases and other conditions. Lines derived from
malignant neoplasms are particularly useful tools for investigating
mechanisms of tumor initiation and development. These cells are
often used as pre-clinical models for the disease, as sources for
biomarker or drug target identification, and as vessels to screen for
efficacy hits and for early toxicity indicators. Because of the
increasing importance of cultured cells in cancer research and other
biomedical studies, cross-contamination of cell lines is becoming a
more frequently encountered problem. It has been reported that
approximately 20% of cell lines are incorrectly designated [21,36–
38]. Nevertheless, researchers infrequently authenticate cell lines
prior to initiating studies or before freezing stocks. The NIH has
recentlyrecognizedtheproblemand hasissuedanoticethatcellline
authentication must accompany all grant applications and all
publications of research findings (http://grants.nih.gov/grants/
guide/notice-files/NOT-OD-08-017.html).
HeLa cells were the first established human cancer cell line [23].
They were quickly distributed worldwide with attendant contam-
ination problems. Cross-contamination of cell lines with HeLa cells
was first reported in 1968 [39]. Among the first established 20
human cell lines, 18 were eventually identified as HeLa cells
[21,39,40]. In the past, various methods were developed to identify
intraspecies contamination of cells in culture. Electrophoretic
polymorphisms of glucose-6-phosphate dehydrogenase (G6PD)
initially played a significant role in identifying HeLa contamination
[41]. Phosphoglucomutase (PGM) electrophoretic polymorphisms
also supported HeLa cell identification [41]. HeLa cells show Type
A G6PD and Type1 PGM profiling. Besides these biochemical
methods, a genetic approach has also been applied: HeLa cells
display characteristic trypsin-Giemsa stained chromosome band
patterns [41]. In addition, the presence or absence of a Y
chromosomecanbeassessedbyfluorescentstaining.The expression
of HLA antigen on the cell surface was an alternative approach to
verify cell identification. This approach revealed that EJ-1 cells
share the same genetic profile with T24 bladder cancer cells [26].
Currently STR profiling of polymorphic markers has replaced these
methods. It is an efficient and reliable method for detecting cross-
contamination of human cell lines. An earlier usage of STR showed
that ECV304 was a contaminant of T24 cells [22,25,28].
Cell line contamination is a significant problem. For example,
one study analyzed 550 leukemia-lymphoma cell lines and
reported that 82 (14.9%) were cross-contaminated with different
Table 2. STR DNA fingerprint analysis of ACCS.
STR Locus
Cell line AMEL CSF1PO D13S317 D16S539 D5S818 D7S820 TH01 TPOX vWA Percent match to ACCS
ACCS X 12 12 9 10 10, 11 6 8 17 100
ECV304 X 12 12 9 10 10, 11 6 8, 11 17 95
T24 X 10, 12 12 9 10, 12 10, 11 6 8, 11 17 87
EJ-1 X 10, 12 12 9 10, 12 10, 11 6 8, 11 17 87
STR profiling of ACCS cells was compared to data in the Japanese Collection of Research Bioresources (JCRB) database (ECV304, T24 and EJ-1 cells). Electrophoretic
profiles of the complete STR markers for ACCS cells are shown in Figures S11 and S12.
doi:10.1371/journal.pone.0006040.t002
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lymphoma origin [42]. Another study reported that the MDA-
MB-435 human breast cancer cell line was thoroughly contam-
inated with the M14 human melanoma cell line [43]. M14 cross-
contaminants have also been found in the thyroid cancer cell line
NPA87 and its sublines, which make it the most frequent
contaminant group in thyroid cancer cells, followed by HT-29
colon cancer contaminants [44].
Figure 2. ACCNS cells were mouse cells and CAC2 cells were rat cells. A cytochrome C oxidase subunit I (COI) DNA barcoding assay was
performed using multiplex species-specific primer sets for 12 species (+, lanes 3, 5, 6 and 7) or 11 species-specific sets without mouse primers (2,
lanes 2 and 4). The PCR products were separated in a 2% agarose gel and visualized with ethidium bromide following amplification of 59 end of COI
region. Lanes 1 and 8: 100 bp ladders. Lanes 2 and 3: ACCNS. Lanes 4 and 5: CAC2. Lane 6: Mixed DNA template from 12 species. Lane 7: no template
DNA. The animals and expected PCR product sizes were as follows; human (391 bp), cat (341 bp), Chinese hamster (315 bp), rhesus monkey (287 bp),
horse (243 bp), African green monkey (222 bp), rat (196 bp), dog (172 bp), mouse (150 bp), rabbit (136 bp), goat (117 bp), and cow (102 bp). The
PCR products were sequenced to confirm that they contained the species-specific nucleotide sequence.
doi:10.1371/journal.pone.0006040.g002
Table 3. Misidentified and cross-contaminated ACC cell lines.
ACC cell line Real identity Actual human malignancy or Species Evidence
ACC2 HeLa Uterine adenocarcinoma STR
ACC3 HeLa Uterine adenocarcinoma STR
ACCM HeLa Uterine adenocarcinoma STR
ACCS T24 Urinary bladder carcinoma STR
ACCNS ? Mouse cells DNA barcoding
CAC2 ? Rat cells DNA barcoding
doi:10.1371/journal.pone.0006040.t003
Misidentified ACC Cell Lines
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cell lines, as reported in recent publications [42,45,46]. As a
consequence, reports with invalid hypotheses and incorrect results
havebeen published.Thus,use ofcontaminatedcelllinesmaycause
significant delays in the development of new treatments or new
biomarkers. They may also add significant costs to the process if
researchers spend time and money investigating false leads.
ACC studies are no exception to this problem [17]. We
performed a PubMed search and found that 75 original research
papers using the cell lines examined in this study were published
from 1991 to 2008 (Table 4). Notably, ACC2 and ACCM were
used in more than 30 published studies. Many of these reports
proposed new therapeutic applications based on results derived
from use of the cell lines. Our study suggests that ACC cell lines
should be authenticated before research involving their use is
performed.
If the contamination identified here is widespread among other
cell lines that are identified as ACC cells, it will be necessary to
establish new ACC cell lines. It will be essential to ensure that the
new cell lines do not become contaminated.
As a first, step prior to the creation of cell lines, researchers
should freeze and store multiple samples of the original material
and then, when a cell line is established, they should perform STR
profiling to confirm that the cells are identical to the donor tissue.
Sporadic ACC tumors often overexpress c-Kit, keratin, S-100
protein, and actin [8]. Detection of these ACC-specific markers is
an alternative approach to quality control of ACC cells. It should
be performed in all new ACC cell lines. After verification, cell line
stocks should be deposited in one or more BRCs before
information about them is published. The quality control
procedures at BRCs may reduce contamination problems.
Additionally, because ACC is composed of duct-type epithelial
cells and myoepithelial cells, it may be prudent to establish each
component separately to avoid one of the cellular components
becoming dominant during passaging.
The genotypes, karyotypes and phenotypes of new cell lines
must be documented by the originators and/or the BRCs using
cells with low passage numbers. This approach will avoid the
effects of extended passage number on selective pressure and
genetic instability in cell lines [24]. Researchers should also include
data concerning STR profiling of donor tissue and the cell line in
publications of studies that use the new cell line. An additional
important measure would be to ensure that all personnel working
with cultured cells are given thorough instructions on how to avoid
contamination. Finally, publications of any ACC research using
ACC cell lines should include cell line authentication. We
anticipate that these efforts will considerably reduce cell
contamination and thus improve the quality of ACC research.
Materials and Methods
Cell lines and cell culture
Cell lines were obtained as follows: ACC2/Sa and ACC3 were
generously provided by Dr. Takashi Saku, Niigata University,
Japan. ACC2/Zh cells were kindly donated by Dr. Naishou Zhu,
Fudan University, Shanghai, PR China. ACCM and ACCNS
were courtesy of Dr. Noriaki Tanaka, Hyogo College of Medicine,
Japan. ACCS was a generous gift from Dr Kanemitsu Shirasuna,
Kyushu University, Fukuoka, Japan. CAC2 was a gift from Dr.
Ruy Jaeger, University of Sa ˜o Paulo, Brazil. HeLa cells were
purchased from the ATCC. All cell lines were maintained as
monolayer cultures in RPMI1640 containing penicillin-strepto-
mycin, nonessential amino acids, sodium pyruvate, L-glutamine
and 10% Fetal Bovine Serum (PAA Laboratories Inc., New
Bedford, MA). They were incubated in a humidified atmosphere
with 5% CO2 at 37uC.
Genomic DNA isolation and short tandem repeat (STR)
DNA fingerprint analysis
Genomic DNA was isolated from cell lines in a clean
environment using the Wizard SV Genomic DNA Purification
system (Promega, Madison, WI). In this system, co-purified RNA
was removed by RNase A. The purity of genomic DNA was
validated by monitoring the OD260 nm/OD280 nm absorbance
ratio [47]. DNA whose ratio was between 1.87 and 1.97 was used
for the further analysis. STR DNA fingerprint analysis was
performed using the Powerplex 1.2 system (Promega). The
following STR markers were tested: AMEL (Xp22.10-22.3 and
Y), CSF1PO (5q33.3–34), D13S317 (13q22–q31), D16S539
(16q24-qter), D5S818 (5q21–q31), D7S820 (7q), TH01
(11p15.5), TPOX (2p23-2pter), and vWA (12p12-pter). A
multiplex PCR reaction was performed using two-color detection
fluorescent dye-linked primers according to the manufacturer’s
manual. We amplified 1 ng of template DNA in a 25 ml reaction
volume. The amplified PCR products were separated by capillary
electrophoresis on a 3730xI DNA Analyzer (Applied Biosystems)
and analyzed using GeneMapper v4.0 software (Applied Biosys-
tems). For comparison, percent match of STR profiling was
calculated between two cell lines according to the following
mathematical formula [15,17]: Percent match (%)=1006(number
of alleles in reference and study samples)62/(total number of
alleles in reference+total number of alleles in study samples).
Cytochrome C oxidase subunit I (COI) DNA barcoding
assay
PCR reactions were performed using multiplex 12 species-
specific primer sets that target the 59 variable region of the COI
gene [33]. The complete list of primer sequences has been
published [33]. PCR products were visualized on 2% agarose gel
stained with ethidium bromide. PCR products were sent for
sequencing analysis to confirm results.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0006040.s001 (0.08 MB PPT)
Figure S1 Electrophoretic profiles of the vWA marker for HeLa,
ACC2/Sa, ACC2/Zh, ACC3, and ACCM cells are shown. A
Table 4. Number of articles citing 6 ACC cell lines.
Cell line Number of articles
ACC2 30
ACC3 14
ACCM 32
ACCS 7
ACCNS 1
CAC2 10
Total 94
A PubMed search revealed that 75 original research papers citing at least one of
the six cell lines analyzed here were published from 1991 to 2008. Some papers
used more than one cell line and, thus, the total number was more than 75
publications.
doi:10.1371/journal.pone.0006040.t004
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PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e6040separate STR analysis from Table 1 and Figure 1 was performed
at the Fragment Analysis Facility, Johns Hopkins University.
Found at: doi:10.1371/journal.pone.0006040.s002 (4.03 MB TIF)
Figure S2 Electrophoretic profiles of the AMEL marker for
HeLa, ACC2/Sa, ACC2/Zh, ACC3, and ACCM cells shown in
Table 1 are presented.
Found at: doi:10.1371/journal.pone.0006040.s003 (1.88 MB TIF)
Figure S3 Electrophoretic profiles of the CSF1PO marker for
HeLa, ACC2/Sa, ACC2/Zh, ACC3, and ACCM cells shown in
Table 1 are presented.
Found at: doi:10.1371/journal.pone.0006040.s004 (1.90 MB TIF)
Figure S4 Electrophoretic profiles of the D13S317 marker for
HeLa, ACC2/Sa, ACC2/Zh, ACC3, and ACCM cells shown in
Table 1 are presented.
Found at: doi:10.1371/journal.pone.0006040.s005 (1.85 MB TIF)
Figure S5 Electrophoretic profiles of the D16S539 marker for
HeLa, ACC2/Sa, ACC2/Zh, ACC3, and ACCM cells shown in
Table 1 are presented.
Found at: doi:10.1371/journal.pone.0006040.s006 (1.80 MB TIF)
Figure S6 Electrophoretic profiles of the D5S818 marker for
HeLa, ACC2/Sa, ACC2/Zh, ACC3, and ACCM cells shown in
Table 1 are presented.
Found at: doi:10.1371/journal.pone.0006040.s007 (1.77 MB TIF)
Figure S7 Electrophoretic profiles of the D7S820 marker for
HeLa, ACC2/Sa, ACC2/Zh, ACC3, and ACCM cells shown in
Table 1 are presented.
Found at: doi:10.1371/journal.pone.0006040.s008 (1.75 MB TIF)
Figure S8 Electrophoretic profiles of the TH01 marker for
HeLa, ACC2/Sa, ACC2/Zh, ACC3, and ACCM cells shown in
Table 1 are presented.
Found at: doi:10.1371/journal.pone.0006040.s009 (1.82 MB TIF)
Figure S9 Electrophoretic profiles of the TPOX marker for
HeLa, ACC2/Sa, ACC2/Zh, ACC3, and ACCM cells shown in
Table 1 are presented.
Found at: doi:10.1371/journal.pone.0006040.s010 (1.87 MB TIF)
Figure S10 Electrophoretic profiles of the vWA marker for
HeLa, ACC2/Sa, ACC2/Zh, ACC3, and ACCM cells shown in
Table 1 are presented.
Found at: doi:10.1371/journal.pone.0006040.s011 (1.88 MB TIF)
Figure S11 Electrophoretic profiles of the AMEL, CSF1PO,
D13S317, D16S539, D5S818, D7S820, and TH01markers for
ACCS cells shown in Table 2 are presented.
Found at: doi:10.1371/journal.pone.0006040.s012 (1.62 MB TIF)
Figure S12 Electrophoretic profiles of the TPOX and vWA
markers for ACCS cells shown in Table 2 are presented.
Found at: doi:10.1371/journal.pone.0006040.s013 (0.83 MB TIF)
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